Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
March 11 (Reuters) - Pfizer PFE.N and Arvinas' ARVN.O experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology